SCHEMBL60054

SCHEMBL60054

CCCCCCCC/C=C/CCCCCCCC[C]1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.45
TRPV1 Q8NER1 1/20 0.45
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
CCR5 P51681 2/20 0.40
TERT O14746 2/20 0.40
GMNN O75496 1/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
APEX1 P27695 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11169645 1.00 FAAH (0.45) FAAHTRPV1ALDH1A1TSHRCCR5
SCHEMBL60055 1.00 FAAH (0.45) FAAHTRPV1ALDH1A1TSHRCCR5
SCHEMBL60761 0.98 FAAH (0.47) FAAHTRPV1ALDH1A1TSHRTERT
SCHEMBL60760 0.98 FAAH (0.47) FAAHTRPV1ALDH1A1TSHRTERT
SCHEMBL9211727 0.94 FAAH (0.47) FAAHTRPV1ALDH1A1TSHRTERT
SCHEMBL9211716 0.94 FAAH (0.47) FAAHTRPV1ALDH1A1TSHRTERT
SCHEMBL4487572 0.90 FAAH (0.50) FAAHTRPV1TERTGMNNUSP2
SCHEMBL7737539 0.88 CCR5 (0.42) ALDH1A1TSHRCCR5LMNAHSD17B10
SCHEMBL734136 0.88 CCR5 (0.42) ALDH1A1TSHRCCR5LMNAHSD17B10
SCHEMBL7738487 0.88 CCR5 (0.42) ALDH1A1TSHRCCR5LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218633-A1 METHODS OF TREATING ORAL MUCOSITIS GALERA LABS, LLC 2023-07-13 US disclosed
US-11612608-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2023-03-28 US disclosed
US-20200215077-A1 METHODS OF TREATING ORAL MUCOSITIS BIOSSIL INC. (CA) 2020-07-09 US disclosed
US-10610533-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2020-04-07 US disclosed
EP-3527079-A1 METHODS OF TREATING ORAL MUCOSITIS Galera Labs, LLC (US) 2019-08-21 EP disclosed
EP-2056675-B1 METHODS OF TREATING ORAL MUCOSITIS GALERA LABS LLC (US) 2019-01-09 EP disclosed
US-20180333421-A1 METHODS OF TREATING ORAL MUCOSITIS BIOSSIL INC. (CA) 2018-11-22 US disclosed
EP-3287464-A1 ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS Abbott Laboratories (US) 2018-02-28 EP disclosed
US-9855279-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2018-01-02 US disclosed
EP-2859916-B1 Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy GALERA LABS LLC (US) 2017-11-29 EP disclosed
WO-1997006830-A1 METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING BIOCONJUGATES OF METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS MONSANTO COMPANY (US) 1997-02-27 WO disclosed
EP-0756495-A1 DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES MONSANTO COMPANY (US) 1997-02-05 EP disclosed
WO-1995028968-A1 DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES MONSANTO COMPANY (US) 1995-11-02 WO disclosed
EP-0679155-A1 MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE. MONSANTO CO (US) 1995-11-02 EP disclosed
EP-0421441-B1 Pantothenic acid derivatives FUJIREBIO KK (JP) 1995-01-25 EP disclosed
EP-0598753-A1 MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE MONSANTO COMPANY (US) 1994-06-01 EP disclosed
WO-1993002090-A1 MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE MONSANTO COMPANY (US) 1993-02-04 WO disclosed
EP-0524161-A1 Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide MONSANTO COMPANY (US) 1993-01-20 EP disclosed
US-5120738-A Cardiovascular disorders FUJIREBIO INC. (JP) 1992-06-09 US disclosed
EP-0421441-A2 Pantothenic acid derivatives FUJIREBIO INC. (JP) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180333421-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO FAAH 3604/4885TRPV1 2795/4885ALDH1A1 664/4885
US-20200215077-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO FAAH 3604/4885TRPV1 2795/4885ALDH1A1 664/4885
US-20230218633-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO FAAH 3604/4885TRPV1 2795/4885ALDH1A1 664/4885
US-10610533-B2 Methods of treating oral mucositis LPO, SOD3, MPO FAAH 3604/4885TRPV1 2795/4885ALDH1A1 664/4885
US-11612608-B2 Methods of treating oral mucositis LPO, SOD3, MPO FAAH 3604/4885TRPV1 2795/4885ALDH1A1 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.